If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
21/09/2026 [08:30:00]
Results 150 to 174 of 174
Absstract of: CN122445571A
The invention discloses a Group 4 subtype medulloblastoma micro-tumor PTC (positive temperature coefficient) model as well as a construction method, an evaluation method and application thereof, and the construction method specifically comprises the following steps: establishing a Group 4 subtype medulloblastoma micro-tumor model, adopting a basic culture medium containing advanced DMEM (dulbecco's modified eagle medium)/F12, and carrying out subtype culture on the Group 4 subtype medulloblastoma micro-tumor model; specific components (glutamine, penicillin-streptomycin-amphotericin, B27 without vitamin A, N2, 2-mercaptoethanol, non-essential amino acid, insulin and the like) are added as a culture medium; the method comprises the following steps: treating a myeloblastoma tumor tissue through a dispersion method, performing in-vitro culture on a tumor single-cell suspension obtained by digestion in combination with a suspension culture system and a low-oxygen environment, and performing culture under predetermined conditions to form a myeloblastoma micro-tumor PTC model containing various tumor tissue source cell types. The model keeps high similarity with the original tumor tissue in the aspects of histopathologic characteristics and molecular genetics characteristics, highly restores the microenvironment characteristics of the original tumor tissue, and can be used for experiments such as drug screening and treatment response prediction.
Absstract of: CN224540318U
The utility model belongs to the technical field of blood glucose testing, and particularly relates to a portable fingertip blood glucose testing box which comprises a box body and an object taking drawer, an opening is formed in the position, close to the bottom face, of the side wall of the box body, the object taking drawer is located in the opening of the box body, and a supporting plate is fixedly connected to the position, close to the bottom face, of the inner wall of the box body. A pressing self-locking rebounding device is assembled on the bottom face of the supporting plate, the end face of the pressing self-locking rebounding device is movably connected with a pressing rebounding device telescopic shaft, and the pressing rebounding device telescopic shaft corresponds to the object taking drawer. The blood glucose test paper and the blood taking needle can be stored in the same container, the one-key pop-up technology is adopted, one blood taking needle and one blood glucose test paper can be popped up at the same time only by pressing down the springback device, operation steps are reduced, pop-up is accurate, and excessive taking of the test paper is avoided.
Absstract of: CN122440182A
The invention provides an intelligent blood glucose concentration detection method and device based on wearable equipment, and relates to the technical field of medical instruments. The method comprises the following steps: inputting a matching degree and a size relationship corresponding to each residual infrared receiver into a subcutaneous tissue feature determination model, and determining subcutaneous tissue features of a skin area where each residual infrared receiver is located; the subcutaneous tissue characteristics of the skin area where each infrared receiver is located and the first average blood glucose concentration of the n initial blood glucose concentrations collected at the n sampling moments are input into an actual blood glucose concentration determination model, and the actual blood glucose concentrations corresponding to the m infrared receivers are determined; the second average blood glucose concentration of the actual blood glucose concentrations corresponding to the m infrared receivers is determined as the blood glucose concentration collected by the wearable device, and the accuracy of the determined blood glucose concentration is high.
Absstract of: CN122440940A
The invention discloses a disposable internal rotation type insulin injection pen, and belongs to the technical field of medical instruments. Comprising a button, a knob, a first transmission mechanism, a second transmission mechanism, a clutch seat and an injection screw, and the first transmission mechanism is switched between a dose adjusting position (connected with the knob and separated from the clutch seat) and an injection position (separated from the knob and connected with the clutch seat) under the action of the button. The second transmission mechanism comprises a scale sleeve and a fixed threaded seat, and the scale sleeve and the first transmission mechanism rotate synchronously. During adjustment, the knob drives the scale sleeve to overcome the pressure spring and move away from the knob end; during injection, the pressure spring releases elastic force to drive the scale sleeve to reset, and sequentially drives the first transmission mechanism, the clutch seat and the screw to rotate synchronously to discharge medicine. According to the scheme, the axial compression spring is adopted, pre-twisting is not needed in assembly, assembly is convenient, and cost is reduced; the independent threaded seat bears core transmission, and the shell no longer bears complex load, so that injection molding difficulty is reduced, and application of metal materials is supported.
Absstract of: CN122440936A
The invention discloses an insulin pen, and relates to the technical field of medical instruments, the insulin pen comprises an insulin pen body, the insulin pen body comprises a pen container, the inner side of the bottom of the pen container is provided with a limiting ring, the inner side of the bottom end of the pen container is in threaded connection with the top end of a refill mounting cylinder, and a refill assembly is mounted in the refill mounting cylinder; the insulin injection device further comprises a refill pressing assembly, an insulin injection control mechanism, a pressing column one-way displacement control mechanism, a pressing column friction force relieving mechanism and an injection amount control mechanism, the refill pressing assembly comprises a pressing column, and the inner side of the limiting ring is vertically connected with the pressing column in a sliding mode. According to the insulin pen, after a needed injection amount is set, the injection amount does not need to be set frequently during injection every time, air in the needle head is very convenient to discharge after the needle head is replaced, air in the needle head can be discharged without independently setting a small insulin discharge amount, operation is convenient, the pressing safety assembly is arranged, and the insulin pen is convenient to use. And the insulin outflow caused by mistaken touch or mistaken extrusion after the insulin pen is stored is avoided.
Absstract of: CN122440181A
The present invention relates to a method for measuring post-translational modification of a protein in a subject. The method includes recording infrared radiation within a predetermined wavenumber range attenuated by the skin of the subject, wherein the skin still adheres to the subject; and comparing the attenuation of the infrared radiation to a predetermined value in order to obtain information about post-translational modification of proteins in the skin. The invention also relates to a corresponding system and to post-translationally modified skin proteins as markers for in vivo diagnosis of diseases, such as diabetes or renal insufficiency.
Absstract of: US20260207096A1
Analyte sensors featuring an enzyme system comprising diaphorase and a NAD-dependent dehydrogenase may be utilized to detect inhibitors of diaphorase, provided that the transfer of electrons to a working electrode is rate-limiting with respect to the diaphorase. Such analyte sensors may comprise a sensor tail comprising at least a first working electrode, a first active area disposed upon a surface of the first working electrode, and an analyte-permeable membrane overcoating at least the first active area. The enzyme system comprises NAD, reduced NAD, or any combination thereof; a NAD-dependent dehydrogenase, such as NAD-dependent glucose dehydrogenase; and diaphorase. Inhibitors of diaphorase that may be detected include, for example, warfarin, dicoumarol, and similar compounds. A second active area may be present to facilitate detection of an analyte differing from the inhibitor of diaphorase.
Absstract of: US20260209692A1
0000 The present invention relates to a basal medium composition for animal cell culture. The basal medium composition for animal cell culture according to the present invention contains a yeast extract, amino acids, an inorganic salt, and a sugar, wherein the amino acids in the composition include cystine and/or cysteine, and glutamine.
Absstract of: US20260207098A1
0000 Embodiments of the invention provide amperometric analyte sensors having optimized elements such as interference rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; an interference rejection membrane disposed on an electroactive surface of the working electrode, wherein the interference rejection membrane comprises poly(vinyl alcohol) (PVA) polymers crosslinked by an acid crosslinker, wherein the crosslinker is a dicarboxylic acid type monomer or a polymer comprising a carboxylic acid group; and an analyte sensing layer. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.
Absstract of: WO2026152526A1
Provided is a refrigeration cup for an insulin pen in which an insulin cartridge is arranged. The refrigeration cup comprises a refrigeration assembly, a cold conduction cylinder (500), a cup lid (100), and a cup body (200). The refrigeration assembly comprises a semiconductor refrigeration sheet (401), a heat conduction member (402), and a heat dissipation fan (403). The semiconductor refrigeration sheet (401) comprises a cold end and a hot end, and the hot end is attached to the heat conduction member (402). The cold conduction cylinder (500) comprises a sealed end (501) and an open end (502), and the cold end is attached to the sealed end (501). The cup lid (100) is suitable for accommodating the refrigeration assembly. The sealed end (501) is relatively fixedly connected to the semiconductor refrigeration sheet (401) and/or the cup lid (100). The cup body (200) comprises a cup wall (201) and a heat preservation cavity (202) defined by the cup wall (201). The open end (502) extends into the heat preservation cavity (202), and the cup lid (100) detachably seals the heat preservation cavity (202). The cold conduction cylinder (500) or the heat preservation cavity (202) defines an accommodating space capable of accommodating at most one or two insulin pens. The accommodating space is also suitable for accommodating the insulin cartridge. The diameter of the accommodating space ranges from 20 mm to 50 mm. By means of limiting the size of the cold conduction cylinder (500), por
Absstract of: US20260207136A1
0000 A system includes a wearable device and a charger case. The wearable device is configured to be positioned on an ear of a wearer, and includes first and second body portions and a connection member mechanically coupled to each of the first body portion and the second body portion. The first body portion and/or the second body portion includes a processor, a memory, and a sensor set including at least one of a pulse oximeter, a photoplethysmogram (PPG) sensor, an accelerometer, a temperature sensor, a proximity sensor, an ambient light sensor, or a gyroscopic sensor. The memory stores instructions to cause the processor to calculate at least one of a blood oxygen saturation level, a pulse rate, a blood pressure level, a blood flow rate, a cardiac output/rhythm, a blood sugar level, a blood carbon monoxide level, a blood nitrous oxide level, or an electrocardiogram of the wearer.
Absstract of: US20260209710A1
0000 A cell culture medium is disclosed. The cell culture medium comprises: a species-specific cell culture medium comprising: bFGF of the species, PDGF-BB of the species, and EGF of the species; and serum of the species. Further disclosed is a canine cell culture medium comprising: canine bFGF, canine PDGF-BB, and canine EGF; and canine serum. A composition is described comprising: a medium comprising: basal medium, sodium bicarbonate, HEPES, L-glutamine, L-alanine, Insulin, hydrocortisone, progesterone, Asc-2-p, holo-transferrin; bFGF of the species, PDGF-BB of the species, and EGF of the species; and serum consistent with the cells of the species; MSC cells of the species. A method of producing exosomes is described, the method comprising: expanding mesenchymal stem cells and/or islet cells in culture, the culture and collecting exosomes released by the mesenchymal and/or adipose stem cells in culture.
Absstract of: WO2026156224A1
A light source is tuned to a range of wavelengths selected for relatively high absorption by glucose, while an optical sensor uses a complementary filter that selectively absorbs in the same spectrum. This optical channel, in combination with a separate, unfiltered reference optical channel, supports a calculation of glucose concentration in target tissue based on a ratiometric comparison of measured light intensities. In embodiments, quantum dots or other techniques can be used to tune the optical spectrum of a light source, while glucose or a similarly absorbing material can be embedded in an optical potting material or the like to create a similarly tuned filter for a corresponding optical sensor. The supporting hardware may usefully be deployed in a wearable physiological monitor for continuous monitoring of glucose (or other target molecules) in the tissue of a user.
Absstract of: WO2026154038A1
A computer implemented method of training a machine learning model configured for predicting a hypoglycemic event for a subject is proposed, comprising: i. (126) receiving at least two time series of glucose sensor data, wherein each time series of glucose sensor data comprises a plurality of glucose measurements measured by a glucose monitoring device (112) configured for detecting glucose in a bodily fluid of the subject, wherein a first time series of the two time series of glucose sensor data is measured at least during and/or after being exposed to a first predefined program of glycemic stimuli, and wherein a second time series of the two time series of glucose sensor data is measured at least during and/or after being exposed to a second predefined program of glycemic stimuli, wherein the second predefined program of glycemic stimuli is different from the first predefined program of glycemic stimuli; ii. (128) forming a first training dataset using the first time series and forming a second training dataset using the second time series; iii. (130) training the machine learning model with the first training dataset and the second training dataset.
Absstract of: US20260209815A1
0000 Embodiments of the invention provide amperometric analyte sensors having elements selected to optimize enzymatic activities associated with such sensors including polymers functionalized with enzymatic mediators as well as methods for making and using such sensors. While embodiments of the invention can be used in a variety of contexts, typical embodiments of the invention include glucose or ketone sensors used in the management of diabetes.
Absstract of: US20260207176A1
0000 A system and method for artificial intelligence (AI)-assisted medical diagnostics. A real-time endoscopic ultrasound (EUS) video stream of a patient's organ, such as the pancreas, is received at a computing device. The EUS video stream comprises a plurality of imaging modalities, including at least grey-scale data and elastography data representing tissue stiffness. One or more processors execute an AI model, which processes the video stream to identify, segment, and characterize a region of interest. A visual output is generated for display on a user interface in real-time, the output comprising the EUS video stream with a graphical overlay that includes a visual indicator delineating the segmented region and a classification label corresponding to the characterization, thereby providing real-time clinical decision support.
Absstract of: WO2026155234A1
The present disclosure provides a culture medium for cell culturing, the culture medium containing a combination of specific components. The present disclosure provides a culture medium which contains a combination of components selected from the group consisting of: (1) a halcinonide component; (2) an ALK4/7 inhibitor or a TGFβ receptor type-1 kinase inhibitor; (3) a BRD7/9 double degradation factor or a BRD7/9 binding molecule (degradation factor); (4) an LATS1/2 inhibitor, a PKA inhibitor, or an AKT1 inhibitor; (5) a CK1/2 inhibitor, an insulin receptor inhibitor, a Tyr kinase inhibitor, a PKA inhibitor or a PKC inhibitor, or an adenosine kinase inhibitor; (6) an E-selectin inhibitor, a VCAM1 inhibitor, or an ICAM1 inhibitor; and (7) an LATS1 inhibitor + an LATS2 inhibitor.
Absstract of: WO2026155233A1
Provided is a culture medium for culturing cells containing specific components. Provided is a culture medium comprising at least one component selected from a group consisting of (1) halcinonides, (2) ALK4/7 inhibitor or TGFβ receptor type 1 kinase inhibitor, (3) BRD7/9 dual degradation factor or BRD7/9 binding molecule (degradation factor), (4) LATS1/2 inhibitor, PKA inhibitor, or AKT1 inhibitor, (5) CK1/2 inhibitor, insulin receptor Tyr kinase inhibitor, PKA inhibitor, or PKC inhibitor or adenosine kinase inhibitor, (6) E-selectin inhibitor, VCAM1 inhibitor, or ICAM1 inhibitor, and (7) LATS1 inhibitor + LATS2 inhibitor.
Absstract of: WO2026156219A1
Provided are methods of deriving a cell population containing pericytes and endothelial progenitor cells from a peripheral blood sample containing non-hematopoielic cells, which rely on culture media supplemented with serum and in certain embodiments also lacking epidermal growth factor, methods of editing mammalian peripheral blood-derived pericytes, and cells generated these methods. Also provided are serum-free defined cell media containing PDGF-beta; VEGF-C; a Notch ligand; a fibroblast growth factor; a TGF-beta superfamily member; an insulin agonist; transferrin; a hepatocyte growth factor; and a Wnt antagonist. The serum-free defined cell media can be used to derive and/or culture pericytes.
Absstract of: WO2026154262A1
A non-invasive diagnosis system, which comprises: a device for collecting a breath sample from a user, which comprises a mouthpiece; a spectrometer for measuring Volatile Organic Compounds, VOCs, in the breath sample; and a processor, wherein the processor is configured to analyse the measured VOCs using one or more machine learning models for classifying the user, based on one or more combinations of the measured VOCs, as healthy, prediabetic, Type 1 or Type 2 diabetes mellitus.
Absstract of: US20260207087A1
0000 Disclosed herein is a wearable device for continuous glucose monitoring including a housing having a top surface opposite a bottom surface. A portion of the top surface is moveable relative to the bottom surface. The bottom surface has an opening and is configured to secure directly to skin. A puck assembly has a sensor, a wire coupled to the sensor, and a plurality of contacts. A rigid member is configured to move relative to the bottom surface. An engagement member is configured to rotate about an axis. A cutting element is coupled to the engagement member. Displacement of the movable portion of the top surface moves the rigid member into contact with the engagement member. The cutting element rotates through the opening to form an incision in the skin then to a locked position within the housing. The sensor and the wire advance through the opening and into the incision.
Absstract of: WO2026155698A1
Various embodiments of the present invention relate generally to stem cell biology, developmental biology, and regenerative medicine. More particularly, various embodiments relate to methods, compositions, culture systems, and kits for directing the differentiation of human pluripotent stem cells, including human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs), into pancreatic lineage cells such as functional islet-like cells. In further embodiments, the invention relates to populations of pancreatic lineage cells produced by the disclosed methods, as well as their use in disease modelling, drug screening, and cell replacement therapies for metabolic disorders such as diabetes.
Absstract of: WO2026154477A1
The present disclosure is directed to embodiments for an automated insulin delivery (AID) device which includes, inter alia, a housing including an adhesive tape configured, to adhere the housing to the skin of a user via. an adhesive tape. The housing houses at least an insulin pump including a single lumen cannula, a glucose sensor including a sensor probe, a processor, an insertion assembly for inserting the single lumen cannula, and the sensor probe within subcutaneous tissue, and an automated-insulin-delivery algorithm (AIDA). The sensor probe at least partially resides within the single lumen cannula, and the AIDA is configured as computer instructions operating on the processor causing the processor to automatically control insulin delivery by the insulin pump according to glucose levels from subcutaneous tissue based on signals received from the glucose sensor.
Nº publicación: US20260211903A1 23/07/2026
Applicant:
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.
Absstract of: US20260211903A1
Integrated glucose monitoring systems, comprising a memory configured to store data relating to at least two glucose measurements of a user, a glucose safe range, and exogenous data. Wherein the at least two glucose measurements of the user are at different time points t1 and t2; a user interface comprising a display; and a processor comprising computer-executable instructions. Wherein the computer-executable instructions determine a rate of change based on the at least two glucose measurements of the user; determine, based on the at least two glucose measurements of the user and the determined rate of change, a projected glucose level at a future time t3; and provide an alarm at the user interface if, based on at least one point of exogenous data, the projected glucose level at future time t3 is outside of the glucose safe range.
BOPI
Electronic site
